- Appointed Mr. James Rae to the Board of Directors. Mr. Rae brings
to ARIUS more than 30 years of experience in manufacturing,
marketing, finance and research & development for pharmaceutical
and biotechnology firms and is currently the President and CEO of
- Promoted Susan Hahn, PhD to the position of Vice President of
- Subsequent to quarter-end, at ARIUS' annual meeting, William
Bodenhamer, retired from ARIUS' Board of Directors.
Mr. Bodenhamer, has been a valued member of ARIUS' Board since
1999, and we would like to thank him for his commitment and the
wise counsel he has provided us with over the years. Replacing
Mr. Bodenhamer, we have appointed Graham Strachan to the Board of
Directors. Mr. Strachan will be a valuable addition to ARIUS as he
has been involved in the Canadian biotechnology sector for twenty
five years. He is the former President and CEO of Allelix
Biopharmaceuticals Inc., has been a founder of several life
science companies and also serves as a Director on several boards
of publicly-listed companies.
- Continued to discuss potential partnering opportunities with
All amounts are in Canadian dollars unless otherwise indicated.
For the three-month period ended February 29, 2008, the Company recorded a net loss of $2,584,081 ($0.06 per share) compared to a net loss of $2,306,695 ($0.05 per share) for the three-month period ended February 28, 2007. The increase in net loss was primarily the result of higher research and development, general administrative and foreign exchange expenses, partially offset by higher revenues.
For the three-month period
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved